Original from: Myriad Genetics
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.
Myriad¡¯s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina¡¯s updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status.
¡°We are pleased to expand our collaboration with Illumina and combine the two companies¡¯ technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling,¡± said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
Combining Myriad¡¯s HRD technology, which is used in MyChoice® CDx tumor-based test, with Illumina¡¯s expertise in comprehensive genomic profiling will enable Myriad to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types. Broad availability of data and the Myriad GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer.
¡°Inclusion of GIS in all Myriad¡¯s Precise Tumor® clinical reports will strengthen the company¡¯s oncology product portfolio,¡± said Burke. ¡°Precise Tumor is a pan-cancer solid tumor comprehensive genomic profiling test, leveraging Illumina¡¯s current TSO 500 technology.¡±
Myriad announced the strategic partnership with Illumina in January 2021 and has expanded its relationship both geographically and technologically since that time.
